Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Newly Diagnosed Light Chain Amyloidosis
NCT07524634Phase 2Not yet recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2026
- Primary completion
- Jun 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in light-chain amyloidosis, sponsored by Case Comprehensive Cancer Center. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
elranatamab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT07524634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524634.